This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Therapy +/- Local Consolidative Therapy in Limited mNSCLC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Puneeth Iyengar
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Puneeth Iyengar
62 views
June 13, 2024

Chapters

NRG-LU002 Trial Overview & Key Takeaways

00:00

Historical Context & Trial Rationale

02:10

Trial Design & Patient Stratification

05:05

Primary Objectives & Radiation Schema

06:33

PFS, OS Rates & Toxicity Findings

09:55

Study Limitations & Concluding Remarks

12:10

0 Comments
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

2024 ASCO® Annual Meeting Insights Hub: Lung Videos

17:22
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths…

Feat. A. Chiang
40:00
ecancer

ASCO® 2024: Highlights and Analysis of Key Solid Cancer Trials

Feat. B. Gyawali
04:26
ecancer

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance vs. Local C…

Feat. P. Iyengar
View All

Related Content

AUTOPLAY
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
14:49
Vivek Subbiah

Year in Review: Precision Medicine

19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
11:45
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxe…

Feat. T. Mok
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

09:37
Luis Raez

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
08:18
MI&T Congressi

ADC in Combination With Immunotherapy for NSCLC

Feat. S. Liu
18:09
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

The Changing Prognosis of Lung Cancer Brain Metastases

Feat. S. Goldberg
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst